Emerging knowledge indicates that non-coding RNAs, including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), have a pivotal role in bone development and the pathogenesis of bone-related disorders. Most recently, miRNAs have started to be regarded as potential biomarkers or targets for various sets of diseases, while lncRNAs have gained attention as a new layer of gene expression control acting through versatile interactions, also with miRNAs. The rapid development of RNA sequencing techniques based on next-generation sequencing (NGS) gives us better insight into molecular pathways regulated by the miRNA-lncRNA network. In this review, we summarize the current knowledge related to the function of miRNAs and lncRNAs as regulators of genes that are crucial for proper bone metabolism and homeostasis. We have characterized important non-coding RNAs and their expression signatures, in relationship to bone. Analysis of the biological function of miRNAs and lncRNAs, as well as their network, will pave the way for a better understanding of the pathogenesis of various bone disorders. We also think that this knowledge may lead to the development of innovative diagnostic tools and therapeutic approaches for bone-related disorders.

Bone disabilities are prevalent across the life-course and affect the skeletal system. Predominantly, they can be a result of degenerative conditions, trauma, developing cancers, and infections associated with inflammations. Consequently, modern strategies of bone repair have been intensively developed, especially in terms of osteogenic and bone turnover molecular markers. The proper recognition of molecular mechanisms engaged in the development of metabolic bone diseases and bone cancers is crucial for development of new treatment options. Many are commonly available, including palbociclib, which is aimed at silencing cyclin-dependent kinase (CDK)4 and CDK6 in breast cancer treatment. However, numerous treatment methods based on molecular pathways still remain under investigation.

Recently, non-coding RNAs, including small non-coding RNAs (i.e., microRNAs [miRNAs]) and long non-coding RNAs (lncRNAs) have gained recognition as another epigenetic layer of regulation in many tissues, including bone. The biomarker validity of both circulating and endogenous non-protein-coding RNAs is of great importance in bone-related diseases and disorders, such as osteoporosis (OP), rheumatoid arthritis (RA), or osteosarcoma (OS). miRNAs, as well as lncRNAs, are considered to be important regulators of gene expression. Their ability to function as key players in the development of pathological conditions has been discussed for many years. Therefore, the high degree of involvement of non-coding RNAs in transcriptomic activity is closely related to their use as prognostic and diagnostic factors. Despite recent advances in non-coding RNA studies, the biology of these molecules still remains unclear. High-throughput technologies, e.g., next-generation sequencing (NGS), have led to the explanation of the understanding of the non-coding RNA world. The proper combination of multidisciplinary and interdisciplinary approaches has proven essential in revealing the complexity of the non-coding RNAs network and to support establishing the importance of their regulatory existence.

The aim of this review is to highlight the connection between miRNAs and lncRNAs, which is clearly observed in the course of osteogenesis. Both miRNA and lncRNA have potential as diagnostic and prognostic markers, and thus growing evidence indicates that they can be considered as therapeutic targets in bone-related diseases. The clinical value and roles of non-coding RNAs are increasing, especially in the field of regenerative medicine. In this review, we emphasize emerging potential of non-coding RNAs as markers of bone turnover in commonly occurring bone-related diseases, such as osteoporosis, RA, and bone cancers (OS). In this review, we describe the role of several miRNAs, classified as osteo-miRs. The review summarizes the current knowledge about the function of miR-21-5p (miR-21-124-3p (miR-124), miR-203-3p (miR-203), and miR-223-3p (miR-233)) in bone biology. Moreover, we provide information about the role of several lncRNAs closely connected with bone metabolism. We described the function of differentiation
antagonizing non-protein-coding RNA (DANCR), taurine upregulated gene 1 (TUG1), metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), and HOX transcript antisense intergenic RNA (HOTAIR) in order to indicate their actual therapeutic potential. Non-coding RNAs presented in the review are widely considered to be important markers affecting proper bone homeostasis in the described bone diseases.

Additionally, we have presented current information regarding crosstalk between selected miRNAs and IncRNAs, indicating their important role as regulators of molecular pathways during osteogenesis.

As of the time of this writing, only 27 original studies were identified by a literature search in PubMed’s collection of articles that are related to non-coding RNA networks. The combined search terms were “IncRNA” and “miRNA” and “network” and “bone.” To date, no review study has been published that referred to all of the assumed requirements. For this reason, in this review we decided to place an emphasis on the connections linking non-coding RNAs and putative mRNAs, which are essential for proper bone metabolism. In this review, we have pointed out non-coding RNAs that have gained attention as potential biomarkers of bone development or future therapeutic targets.

Biological Functions of Non-coding RNAs

Biology of miRNA

miRNAs (miRs) are small endogenous non-coding molecules, 19–25 nt in size. Their main function is regulation of post-transcriptional silencing of target genes. A single miRNA can target many mRNAs and influence the expression of hundreds of genes involved in functional signaling pathways essential for the survival, proliferation, or differentiation of cells. For example, miR-15a and miR-16-1 are considered to be crucial molecules that inhibit cyclin D expression and suppress OS progression. It was proven that miRNAs regulate the expression not only of mRNA, but also other non-coding RNAs such as IncRNAs. For instance, it has been demonstrated that miR-125b expression is negatively correlated with MALAT1 expression. Furthermore, the HCA1 transcript level is highly associated with miR-1 activity, due to a binding region for miR-1 in the HCA1 structure. The well-known mechanism of miRNA action reduces the expression of targeted mRNAs. The miRNAs, due to their complementarity to the sequence of mRNAs, are able to interact with them and regulate their expression. The most well-described mechanism of miRNA-mRNA interaction is via the 3’ UTR region of target mRNAs, resulting in suppressed expression. Moreover, the interaction of miRNAs with other regions, such as the 5’ UTR, coding sequence, and gene promoters, has also been noted. It has been shown that miRNA interaction with the promoter region may induce transcription in certain conditions. The described modes of miRNA-mRNA interactions are still being studied in order to depict their functional significance.

Single miRNAs may have a plethora of effects and can be regarded as pleiotropic molecules. For example, miR-21 is a regulator of many genes, inducing tumorigenesis, and thus is often considered to be a major onco-miR. At the same time, it is an important molecule regulating pro-osteogenic genes, facilitating the proliferation and differentiation of osteoblast precursors. The levels of miRNAs are regulated by mechanisms similar to other RNAs such as transcriptional activation and inhibition, epigenetic repression, and degradation. It has been proven that a miRNA expression profile changes, depending on the physiological state of the organism. Therefore, they are often used as diagnostic markers, alone or with other molecules, including mRNAs. For instance, tremendous metastatic potential of tumors is associated with a high miR-21 level and correlates with elevated expression of cyclin D, which plays a key role during cancer cell proliferation. It is therefore a valuable prognostic marker associated with a poor prognosis.

In the canonical miRNA biogenesis pathway, miRNA genes are transcribed by Pol II (polymerase II). The long primary transcripts have a local hairpin structure where the miRNA sequence is embedded. In humans, many canonical miRNAs are encoded within introns of coding and non-coding transcripts. However, some miRNAs are encoded within exonic regions. After transcription, the primary miRNA (pri-miRNA) is maturated by a nuclear microprocessor consisting of an RNase III Drosha and a DGC8 cofactor. The essential role of miRNA during an organism’s development has been proven, because deficiency of RNase III Drosha/DGC8 causes lethality in early embryogenesis.

Following Drosha processing, the created pre-miRNA is exported to the cytoplasm through exportin 5 (XPO5) and forms a transcript complex with guanosine triphosphate (GTP)-binding nuclear protein. In the cytoplasm, pre-miRNA is cleaved by Dicer (RNase III endonuclease). This processing involves the removal of the terminal loop, resulting in small RNA duplex creation. Furthermore, the duplex generated by Dicer is loaded onto a protein called AGO (Argonuate). This complex is known as RISC (RNA-induced silencing complex). Meanwhile, the passenger strand of the miRNA duplex is degraded and an active single guide strand recognizes the mRNA transcript. This specific binding inhibits translation and promotes the degradation of miRNA targets.

The biogenesis of miRNA may also occur by alternate, non-canonical pathways, including both DROSHA-independent and DICER independent processes; however, the role of non-canonical miRNAs in bone biology is not well described.

Furthermore, miRNAs are released into the bloodstream, in part through active secretion. About 90% of extracellular miRNAs are bound to AGO proteins, and only 10% are packed in apoptotic bodies, exosomes, or high-density lipoprotein (HDL). Circulating miRNAs actively regulate bone metabolism and thus can be regarded as “fingerprints” for many bone-related diseases, such as osteoporosis or bone tumors. Circulating miRNAs are effectively detectable in liquid biopsies, including plasma, serum, and urine. These are minimal or even non-invasive sources of biomarkers with great potential for diagnostics and clinic application, because circulating miRNAs are more stable in fluids. However, the levels of circulating miRNA are lower than those found in tissues and cells. Nevertheless, liquid
biopsies as a source stable and reliable markers gives a huge advantage in terms of treatment of bone diseases in which biopsy may be problematic.\textsuperscript{19}

Given the fact that miRNAs are engaged in the progression of many human diseases, they are a significant potential diagnostic and prognostic factor. Moreover, recent technological advances have contributed to the significant growth of miRNA validity and enhanced strategies of miRNA-dependent therapies.

**Biology of lncRNAs**

lncRNAs are a family of long (200–100,000 nt long) transcripts with very low protein-coding potential and a structure similar to mRNA. However, some lncRNAs can encode short peptides. Transcripts derived from lncRNAs constitute 4%–9% of the mammalian genome, in comparison to protein-coding sequences, which are 1% of the genome.\textsuperscript{4} Recent studies have shown that lncRNAs play a crucial role in developmental processes and that they are responsible for nuclear chromatin structure regulation as well as gene expression. Nonetheless, there are also opinions that lncRNAs are transcriptional noise and a by-product of RNA Pol II transcription.\textsuperscript{4} The expressed amount of different lncRNAs varies in different tissues, indicating that they are tissue-specific molecules, similarly to miRNAs. Furthermore, the general amount of expressed lncRNAs in every cell is lower than the quantity of miRNA transcripts. Moreover, interspecies homology of lncRNA sequences is relatively low compared to miRNAs. Nevertheless, a certain degree of conservation in the promoter region and exon area of lncRNAs is observed, which suggests that these molecules are biologically significant.\textsuperscript{4} lncRNAs are expressed in a controlled manner, similarly to morphogens, and have been indicated as crucial regulators of various developmental pathways during organogenesis.\textsuperscript{20} For example, it was shown that lncRNAs are a vital regulator of osteogenesis induced in a progenitor derived from a mesenchymal lineage.\textsuperscript{21} However, lncRNAs are also identified as essential regulators of many pathological processes such as osteoporosis or osteoarthritis.\textsuperscript{22} Accumulating evidence has demonstrated that dysregulation of lncRNAs is an important component in the gene regulatory networks during the development and progression of cancer. Thus, lncRNAs are being considered as potential targets in terms of cancer treatment, or biomarkers with diagnostic and prognostic potential.\textsuperscript{23}

The mechanism of lncRNA action is highly complex and has not yet been fully understood, due to initial knowledge about this type of RNA. It is thought that lncRNAs affect mRNA functionality through various pathways. It was proved that lncRNAs participate in gene expression patterns at the transcriptional and post-transcriptional levels.\textsuperscript{24} First, lncRNAs can recruit a chromatin remodeling complex to specific sites and regulate the expression process. Second, lncRNAs can regulate transcriptional expression through blocking the promoter region, interacting with RNA-binding proteins, or regulating the activity of transcription factors. Moreover, lncRNAs can form double-stranded RNA complexes with mRNA at the post-transcriptional level.\textsuperscript{4}

Many efforts are being made in terms of clarification of the biological function of lncRNAs, both as a regulator of essential developmental pathways and as regulators of tumorigenesis. In this review, we summarize the knowledge regarding the function of lncRNAs as pro-osteogenic factors (Figure 1).

**The Role of Selected Non-coding RNAs in Bone Biology and Disease Pathogenesis**

The maintenance of bone homeostasis is preserved by the activity of non-protein-coding RNAs. Both miRNAs and lncRNAs are extremely important factors that lead to proper cell functionality by affecting the expression of crucial genes.\textsuperscript{13,23} However, the supportive roles of several molecules have been explored more extensively. Apparently, this is a result of certain dependencies that link these non-coding RNAs into clear and well-established signaling pathways essential for the maintenance of homeostasis. Moreover, researchers...
have started to pay attention to the specific crosstalk between lncRNAs, miRNAs, and targeted mRNAs. More recent studies have started to show the great importance of specific non-coding RNAs and their relationship with regulated genes. Additionally, it has been proven that miRNAs significantly modulate mRNA expression, while lncRNAs are responsible for the functioning of both miRNAs and mRNAs.

The essential functions of miR-21 and miR-124 in bone tissue turnover were previously described in detail. This pair of miRNAs works in an opposite way and takes part in bone-dependent disease progression. miR-21 is known from its engagement in the process of osteogenic differentation of bone marrow-derived mesenchymal stem cells (BMSCs), as well as maintaining proper bone remodeling. However, it can also contribute to the development of bone neoplasms. In contrast, miR-124 leads to aggressive osteoclast invasion, which leads to active bone resorption and bone metabolism disorders, such as osteopenia or osteoporosis. Furthermore, the potential osteogenesis modulatory abilities of miR-203 and miR-223 remain under investigation and need to be clarified in subsequent experimental analyses. This pair of miRNAs actively participates in both processes, i.e., bone mineralization and bone resorption; however, the regulatory roles of these molecules remain unclear. Furthermore, TUG1, MALAT1, and HOTAIR are IncRNAs that are among the important regulators of tumorigenesis. They are regarded as future molecular targets with extremely high prognostic and diagnostic potential. In addition, the IncRNA DANCR is known for its essential engagement into the bone turnover dysregulation that leads to systemic bone disorder development, e.g., osteoporosis (Figure 2). The mechanisms of action of these molecules strictly refer to bone-related disorders, and for that reason they are broadly described in this review. Data referring to the molecular network of presented molecules is also provided.

**miR-21**

The role of miR-21 as a molecule regulating osteogenesis has been widely investigated, due to an important connection between miR-21 expression and development of bone disorders, such as osteoporosis, osteoarthritis, or bone cancers. The role of miR-21 has been tested using various osteoprogenitor cells. For example, it was shown that miR-21 promotes the level of osteogenic differentiation and increases matrix mineralization in osteogenic cultures of mouse pre-osteoblasts, i.e., the MC3T3-E1 cell line. The study showed that Smad7, which inhibits transforming growth factor β (TGF-β) signaling, is a direct target of miR-21 in MC3T3-E1 cells. Similarly, it was shown that miR-21 is crucial for mineralization capability of BMSCs, and that this process is also regulated by the Smad7-Smad1/5/8-runt-related transcription factor 2 (Runx2) pathway. Our recent data showed complex engagement of miR-21 in the process of osteo-blast-osteoclast coupling. We have confirmed previous studies showing that inhibition of miR-21 expression in MC3T3-E1 cells causes a decrease in mRNA expression of crucial osteogenic markers, such as osteocalcin (Ocl), osteopontin (Opn), collagen type I, and Runx2. Furthermore, we confirmed that MC3T3-E1 cells with lowered expression of miR-21 did not support the osteoclastogenesis process, which might be related to the fact that its targets, such as Opn or receptor activator of nuclear factor κB ligand (RANKL), are regulated in a dynamic manner in the process of osteogenesis.

Other studies conducted with the use of MSCs have shown similar close dependencies. In human BMSCs (huBMSCs) the elevated expression of miR-21 affects the overexpression of typical osteogenic markers, such as RUNX2 or osteonectin (OCN). Additionally, the key targets of miR-21, including SRY-box 2 (SOX2), one of the four genes promoting induced pluripotent stem cells (iPSCs), and sprout homolog 2 (SPRY2), negatively regulate the extracellular signal-regulated kinase-mitogen-activated protein kinase pathway. Furthermore, the overexpression of miR-21 can repress the expression of interleukin (IL)-6 and IL-8, which are involved in the Wnt signaling pathway. Moreover, Wnt signaling is highly engaged in cell commitment and maintenance of bone homeostasis. Therefore, therapy based on miR-21 delivery could simultaneously relieve the symptoms of RA.

In contrast, miR-21 plays a vital role in FLS (fibroblast-like synoviocyte) invasiveness and significantly affects the expression of matrix metalloproteinases. Moreover, the inhibition of miR-21 activity downregulates the expression of TGF-β and Smad5 but increases the Smad7 transcript levels. Thus, inhibition of miR-21 could serve as a favorable therapeutic target diminishing FLS metabolic activity.
and lowering the symptoms of joint diseases. Moreover, miR-21 seems to be a crucial factor that affects the expression of pro-inflammatory cytokines, both in vitro and in vivo during periodontitis.31

miR-21 is commonly known as an oncomiR and is significantly overexpressed in many cancers, including OS.11 The high level of miR-21 is correlated with initial metastasis, poor response to neoadjuvant chemotherapy, and reduced overall survival rate.32 The expression of miR-21 is also positively correlated with the presence of lung metastases in OS patients. Therefore, it can serve as a potential biomarker for the early diagnosis of OS and considered to be a future anti-cancer target.32,33

Bearing in mind the significance of miR-21 in bone homeostasis maintenance, novel kinds of molecular therapy have been developed. miR-21 can be used not only as diagnostic factor in cancer therapy, but especially as an important therapeutic target in many bone diseases. Modern methods based on targeted miR-21 inhibition can improve the effectiveness of common anti-cancer therapies and increase the survivability of patients.34,35 Furthermore, the targeted delivery of miR-21 can produce excellent results in the regeneration of bone fractures.36,37

miR-124

miR-124 is a highly conserved miRNA, and it is overexpressed in many cancers, such as breast cancer, gastric cancer, or glioblastoma.38 Other reports have demonstrated that miR-124 has a strong inhibitory effect on various human neoplasms, such as gliomas, sarcomas, or liver cancers.39-41 Researchers have found various roles of miR-124, e.g., cell cycle arrest, epithelial-to-mesenchymal transition (EMT), cancer stem formation, induction of apoptosis, or even metastasis creation. Therefore, it might be regarded as a good target for designing novel anti-cancer therapeutic strategies.38 In bone cancers, miR-124 is considered to be potential anti-cancer agent for OS treatment, due to suppressing growth and aggressiveness of this cancer cells.41,42 Transfection of miR-124 significantly decreases integrin expression and inhibits OS growth, proliferation, migration, and formation of metastases. It also attenuates OS resistance to various drugs, such as tunicamycin, by downregulation of P53 and Bcl-2 genes.41 Additionally, miR-124 suppresses TGF-β expression in tumor cells.41 The inhibition of OS aggressiveness suggests that miR-124 can be a potential anti-cancer target for OS therapy. Moreover, it was also demonstrated that miR-124 negatively regulates the process of osteogenesis and proper bone regeneration of BMSCs.43 miR-124 negatively affects osteogenic differentiation of MSCs and in vivo bone formation. It acts as an endogenous attenuator of several genes belonging to the homeobox transcription factor gene family, e.g., Dlx5, Dlx3, and Dlx2 expression, by binding the 3' UTRs of these genes.29 The members of the DLX gene family are responsible for bone development and the healing of fractures. For this reason, miR-124 is considered to be an anti-osteogenic molecular marker. In addition, miR-124 targets CDK2 (cyclin-dependent kinase 2) and MPC-1 (monocyte chemotactic protein-1), which are involved in the inflammatory process in RA.41 Previous studies have indicated that miR-124 directly targeted osterix (Otx) expression. Osterix is expressed by osteoblasts and is predominantly responsible for bone formation and homeostasis by promotion of osteoblast differentiation and maturation.45 Therefore, the therapy based on knockdown of miR-124 would be the most efficient in treatment of both osteoporosis and RA.

Interestingly, the high concentration of miR-124 downregulates the expression of glycogen synthase kinase 3β (GSK-3β). This molecule is a significant marker leading to inhibited differentiation of ligament fibroblasts into osteoblasts. Hence, high expression of miR-124 can accelerate the progression of ankylosing spondylitis, which is connected with spastic and spinal joint disabilities, as well as pathological ossification.46

miR-203

miR-203 overexpression is primarily related to downregulation of Runx2 expression, the key factor in osteogenesis.47 Laxman et al.58 proved that overexpression of miR-203 inhibits osteoblast differentiation, whereas inhibition of miR-203 stimulates alkaline phosphatase (ALP) activity and bone matrix mineralization. It was also shown that miR-203 negatively regulates BMP-2 (bone morphogenetic protein 2) expression by suppressing Dlx5, which is one of the key factors in bone repair. However, miR-203 was also found to be essential in the shift from osteogenic differentiation to adipogenic differentiation of BMSCs in postmenopausal osteoporosis. The transfection of miR-203 led to elevated expression of osteogenic genes such as Runx2 or ALP in osteoporotic samples.49 Furthermore, the miR-203 level is up-regulated in RA-delivered tissues.50 Elevated levels of miR-203 lead to increased secretion of matrix metalloproteinase (MMP)-1 and IL-6 via the nuclear factor kB (NF-kB) pathway and in this way activate the phenotype of synovial fibroblasts in RA.31 Hence, miR-203 plays the role of a pro-inflammatory and joint-destructive factor in RA. miR-203 is also associated as a strong tumor suppressor. Huang et al.52 have shown that transfection of miR-203 inhibits TGF-β-induced EMT, migration, and invasive ability in non-small-cell lung cancer by targeting Smad3. However, it was also shown that miR-203, predominantly associated with EMT, was significantly elevated in plasma samples of ovarian cancer patients.53 Moreover, miR-203 acts as a strong tumor suppressor in OS cells, regulating RUNX2 and RAB22A expression.53,55 Moreover, Liu and Feng (2015) indicated anti-tumor properties of miR-203 in OS cell lines and tissues. miR-203 targets TANK binding kinase 1 (TBK1), which was found to be upregulated in OS samples.50 In this way, miR-203 may act as a novel molecular target in bone cancer treatments. Furthermore, analyses conducted on rat BMSCs suggested that miR-203 is highly engaged in downregulation of phosphatidylinositol 3-kinase (PI3K) expression. Hence, it may decrease the PI3K/Akt signaling pathway and impair the viability of BMSCs, an extremely important population of progenitor cells ensuring proper bone metabolism and regeneration.57

Nevertheless, bearing in mind the dual and complex nature of miR-203 in osteogenic differentiation, as well as its significant impact on
w

the serious progression of metabolic diseases and development of various neoplasms, further in-depth analyses targeted on miR-203 must be conducted.

miR-223
Moran-Moguel et al.\(^58\) proved that overexpression of miR-223 significantly inhibits osteoclastogenesis in osteoporosis patients. miR-223 promotes osteoblast differentiation of murine MC3T3-E1 cells by regulation of HDAC2 (histone deacetylase 2). HDAC2 acts as a negative regulator of osteogenesis.\(^79\) However, miR-223 is additionally engaged in osteoclast differentiation by promotion of CSFR1/M-CSFR expression.\(^8\) On account of the dual effect in stimulating osteoclast differentiation and inhibiting osteoblast differentiation, the role of miR-223 as a novel therapeutic target should be further analyzed. In addition, it has been shown that miR-223 can prevent joint destruction in RA patients.\(^58\) miR-223 is downregulated in serum collected from RA patients, but it is significantly upregulated in patients with anti-TNF therapy.\(^61,62\) When it comes to bone neoplasms, miR-223 could be a novel pharmacological marker of OS, due to inhibition of metastasis progression.\(^86,84\) It was found that miR-223 decreased the expression of PARP1, CtIP, and Pso4, which are significant components of alternative non-homologous end joining (aNHEJ). In most cells, the high level of miR-223 represses aNHEJ, decreasing the risk of chromosomal translocation and reducing the probability of the development of malignancy.\(^87\) However, miR-223 represents a crucial component of multiple myeloma development. It was shown that the miR-223 transcript level was upregulated in huBMSCs delivered from multiple myeloma patients. This could be a result of a senescence-like state that is induced by activation of stromal cells by multiple myeloma cells. Moreover, miR-223 seems to regulate important tumor-supportive cytokines, such as VEGF and IL-6.\(^86\)

IncDANCR
The last evidence suggested that DANCR is one of the vital factors involved in the process of cell differentiation. It plays a crucial role in osteogenic differentiation of various types of cells, including stem cells. Furthermore, its contribution to the onset and development of osteoporosis is increasingly recognized. The downregulation of DANCR promotes the osteogenic differentiation of human periodontal ligament stem cells and human fetal osteoblastic cells. It has been shown that high expression of DANCR suppresses the differentiation of human dental pulp cells (hDPCs) by the Wnt/β-catenin signaling pathway into odontoblast-like cells. Moreover, upregulation of the DANCR transcript level blocked mineralized nodule formation and the expression of crucial odontoblast markers, such as DMP-1 and DSPP.\(^67\) Additionally, DANCR knockdown enhances the levels of mRNA expression of osteogenic marker genes and mineralized matrix deposition in huBMSCs.\(^24,68\) Silva et al.\(^69\) have demonstrated that DANCR is overexpressed in monocytes in osteoporosis. Importantly, research has shown that media delivered from monocytic cell cultures, which have overexpressed DANCR, are characterized by increasing bone-resorbing activity in mouse bone cultures. The high level of this non-coding RNA is related to a significant and sudden increase of TNF-α expression, which is one of the most important inflammatory markers. The high expression of TNF-α is predominantly associated with osteoclast differentiation during osteoporosis progression. Furthermore, DANCR promotes RANKL-induced osteoclast formation, which also affects the development of osteoporosis.\(^69\) TNF-α is additionally strongly correlated with the development of RA, and it is called the “top of a pro-inflammatory cascade,” which means that this molecule plays a crucial role in the cytokine network of RA.\(^70\) Inhibition of DANCR expression, for example using antisense molecules blocking the DANCR expression, may yield satisfactory results in osteoporosis, as well as RA therapy. Importantly, note that IncDANCR is also highly engaged in OS cell proliferation.\(^71\) It binds miR-33a-5p, which leads to upregulated expression of AXL (AXL receptor tyrosine kinase). AXL is abnormally expressed in OS patients, regulates tumor cell self-renewal, and indicates a poor prognosis. Additionally, due to AXL upregulation, it enhances expression of proteins in the AXL-Act pathway.\(^71\) This signaling pathway regulates colony formation and EMT of the cancer stem cells (CSCs). On account of these facts, it seems to be a key molecule in many bone pathological pathways, including bone cancers.

IncTUG1
TUG1 is an evolutionary conserved and common lncRNA present in various osteogenically induced MSCs, such as PDLCs (periodontal ligament stem cells) or TPSCs (tendon stem/progenitor cells).\(^72,73\) It is considered to be a key factor facilitating the osteogenic differentiation of progenitor cells. It was shown that TUG1 positively regulates Runx2 expression by sponging the miR-204-5p. Therefore, one of the therapeutic strategies for the treatment of fractures in osteoporotic patients included a combination of pro-TUG1 and anti-miR-204 therapy at the same time, as a novel bone recovery approach.\(^74\) Sacchetti et al.\(^74\) have proved the validity of the miR-204-Runx2 axis, as well as the miR-211-Runx2 axis, in osteoporosis progression. Investigations carried out on murine MSCs indicated that enforced expression of miR-204 inhibited osteogenesis and rescue adipogenesis of the cells. The intrinsic properties of MSCs are significantly altered in postmenopausal osteoporotic patients. They are characterized by poor osteogenic capability and increased adipogenic abilities. It is also known that osteoporosis and obesity often occur together.\(^75\) Therefore, future treatment methods of osteoporosis should be focused not only on elevation of the osteogenic abilities of MSCs, but on their inhibition of adipogenesis as well. Similarly to miR-204, the miR-211 molecule is also negatively associated with Runx2 expression.\(^71\) The high levels of these markers are associated with low Runx2 level and dysregulated osteogenic processes. However, TUG1 is abnormally overexpressed in OS cells, which pathogenically upregulates the Runx2 transcript level and promotes the development of OS.\(^24,76\) Li et al.\(^77\) indicated that the overexpression of TUG1 is associated with miR-132/SOX4 axis dysregulation. Lowered expression of miR-132-3p is associated with TUG1 overexpression, and this has a great impact on SOX4 upregulation and OS progression. The knockdown of TUG1 also markedly inhibits the expression of the MET and phosphorylated (p)-AKT signaling pathway, which is revealed by increased apoptosis rate and cell growth suppression in OS cell lines Saos-2 and MG-63.
Additionally, the inhibition of TUG1 expression significantly reduces the cisplatin resistance of these OS lines.\(^7\) Furthermore, TUG1 is associated with poor prognosis for osteoarthritis patients, and the elevated expression of this lncRNA promotes osteoarthritis-induced degradation of chondrocyte extracellular matrix via the miR-195/MMP-13 axis.\(^7\)

**IncMALAT1**

The lncRNA MALAT1 is a molecule predominantly considered to be an important amplifier of osteogenic differentiation of cells. MALAT1 functions as a sponge molecule of miR-204-5p and upregulates the expression of Smad4 (mothers against decapentaplegic homolog 4). The same sponging abilities against the miR-204-5p molecule are shown by IncTUG1.\(^24\) Smad4 activation promotes the expression of ALP and Ocl, considered to be essential osteogenic markers. Thus, MALAT1 promotes bone formation and mineralization. This way, another alternative OP treatment could be based on anti-MALAT1 and anti-miR-204-5p therapy.\(^1\) Moreover, MALAT1 sponges miR-30 and promotes osteoblast differentiation of ASCs (adipose tissue-derived MSCs) by significantly promoting the expression of Runx2.\(^70\) Interestingly, MALAT1 is responsible for downregulating miR-124 expression, therefore affecting ALP, Runx2, and Ocn levels and finally promoting osteogenesis of MSCs.\(^81\) The coupling mechanism between MALAT1 and miR-124 could be a remarkable and efficient direction for future osteoporosis therapy. Furthermore, MALAT1 expression was proven to be reduced in synovial tissues of RA patients.\(^82\) Li et al.\(^83\) indicated that knockdown of MALAT1 could stimulate the expression of pro-inflammatory cytokines, including IL-6, IL-10, and TNF-α. MALAT1 could also suppress the expression of CTNNB1 and modulate the Wnt signaling pathway. These findings suggest an inhibitory effect of MALAT1 on the proliferation and inflammation of FLSs, which participate in the pathogenesis of RA, by inhibiting the Wnt pathway. Thus, MALAT1 is suggested to be a perfect candidate for an OP and RA therapeutic target.

In contrast, in cartilage tissues collected from healthy and osteoarthritis patients, MALAT1 was shown to be significantly upregulated. Moreover, MALAT1 inhibits miR-150-5p expression, which has a great impact on elevated AKT3 expression. Thus, MALAT1 is responsible for cartilage cells apoptosis, extracellular matrix degradation, and osteoarthritis development via the miR-150-5p/AKT3 axis.\(^83\) However, it was additionally proven that MALAT1 promotes the creation of metastases in OS patients.\(^84\) Upregulation of this molecule is associated with a high expression level of SOX4 or activation of the Wnt/β-catenin signaling pathway.\(^85,86\)

**IncHOTAIR**

HOTAIR is considered to be a significant diagnostic marker for many neoplasms, including breast cancer, cervical cancer, or colorectal cancer.\(^87-89\) Moreover, HOTAIR is considered to be one of the first tumor-related lncRNAs to have been discovered. It is associated with metastasis development and poor patient prognoses. In OS, HOTAIR was detected to be upregulated and coupled with P53 expression. This indicates HOTAIR involvement in the P53-mediated apoptosis pathway in OS cells.\(^90\) It has been proved that HOTAIR promotes the proliferation and invasion of OS cells by the AKT/mTOR signaling pathway.\(^91\) However, it is also involved in bone regeneration from MSCs.\(^1\) HOTAIR reduces the expression of mir-17-5p and elevates the Smad7 transcript level at the same time, and thus Smad7 is a target of miR-17-5p. Smad7 is an important factor that reduces osteogenic potential of the bone. Therefore, the knockdown of HOTAIR significantly upregulates the expression of miR-17-5p, suppresses Smad7 activity, and finally increases the transcript levels of Runx2, collagen 1, and ALP.\(^92\) Furthermore, HOTAIR is considered to be an important factor in alleviation of RA. It was noted to be downregulated in lipopolysaccharide (LPS)-treated chondrocytes and RA mice. However, the transfection of HOTAIR increased cell proliferation and inhibited inflammation in RA mice. It can play a protective role in RA by regulation of the NF-kB signaling pathway. HOTAIR reduces the expression of miR-138, which activates HDAC4/PGDN or HDAC4/NF-kB signaling.\(^93\) It also inhibits the P65, IL-1β, and TNF-α transcripts,\(^94\) which participate in the development of RA. In contrast, it has been shown that HOTAIR is upregulated in osteoarthritis patients and indicates elevated expression of MMPs, as well as chondrocyte apoptosis. Therefore, the silencing of IncRNA HOTAIR could result in better prognoses for osteoarthritis patients.\(^95\)

Table 1 summarizes the involvement of selected non-protein-coding RNAs in the maintenance of bone homeostasis. Their functionality in the course of osteogenesis and tumorigenesis is summarized. Additionally, we mention their targets and examined cell lines (Table 1).

### Crosstalk between miRNAs and lncRNAs for Proper Bone Homeostasis

Non-coding RNAs are emerging as critical regulators of processes associated with bone metabolism, able to modulate complex cellular processes. Both miRNAs and IncRNAs act as fine-tuning molecules playing a crucial role in governing the expression of bone-related genes. It has been reported that IncRNAs are species-specific regulators of various metabolic processes. They may function as competing endogenous RNAs (ceRNAs) that can interact with miRNAs by competitively binding their common miRNAs. In bone tissue, non-coding RNAs are responsible for processes that are crucial for proper musculoskeletal system functions, such as bone turnover or tissue regeneration. However, minor shortcomings in the functionality of expanded networks between non-coding RNAs and miRNAs may contribute to pathological changes of the tissue structure. In addition, miRNAs and IncRNAs regulate the proliferation and differentiation of bone-forming and bone-resorbing cells.\(^96\)

**IncMALAT1** serves as a sponge for miR-30 and miR-124 and elevates the differentiation of osteoblasts. In addition, MALAT1 inhibits the activity of miR-204 and thus increases the Smad4 level, which finally leads to proper osteoblast functionality.\(^4,90,91\) Furthermore, miR-204 as well as miR-211 are blocked by IncTUG1.\(^24,73\) Therefore, TUG1 serves as a positive factor in osteoblast activity and proper bone mineralization. **IncHOTAIR** sponges miR-17-5p, which leads to
Table 1. List of Selected Non-coding RNAs, Their Functions, and Targets

| lncRNA     | Impact on Osteogenesis | Role in Tumorigenesis | Examined Cell Lines                        | Targets                                      | References |
|------------|------------------------|-----------------------|--------------------------------------------|----------------------------------------------|------------|
| miR-17-5p  | downregulation         | oncogene              | huASCs, MC3T3-E1, MG-63, U-2 OS, Saos-2, 143B | SMAD family proteins, RUNX2, OCN, OPN, OCL, COL-1, MMP-9, OPG, RANKL, RANK, IL-6, IL-8 | 106–108    |
| miR-21     | upregulation, downregulation (?/?) | oncogene              | huBMScs, MC3T3-E1, 4B12, MG-63, U-2 OS, Saos-2, HOS, 143B | TGF-β family proteins, DLX family proteins, OSX, CDK2, MIP-1 | 34, 41, 45–46 |
| miR-124    | downregulation         | suppressor gene       | huBMScs, MG-63                            | ERK/MAPK signaling, SDF-1, PI3K/AKT pathway | 116–118    |
| miR-149    | downregulation         | suppressor gene       | huBMScs, MG-63, U-2 OS, Saos-2, HOS, 143B | RUNX2, DLX5, MMP-1, SMAD3, TGF-β family proteins, IL-6, RAB22A, TBK1 | 47, 49, 51, 54–56 |
| miR-203    | upregulation, downregulation | suppressor gene       | huBMScs, huH226, MG-63, U-2 OS, Saos-2    | HDAC2, CSF1/M-CSF, CDH6                      | 185, 180, 190 |
| miR-223    | upregulation           | suppressor gene       | MC3T3-E1, huBMScs, 143B, U-2 OS           | TFN-α, RANKL, miR-33a-5p, miR-216a-5p/ SOX5  | 69, 76, 110 |
| IncDANCR   | downregulation         | oncogene              | huBMScs, human monocytes, 143B            | TNF-α, RANKL, miR-33a-5p, miR-216a-5p/ SOX5  | 24, 74, 77 |
| IncTUG1    | upregulation           | oncogene              | huPDL5Cs, huTPScs, huBMScs, MG-63, U-2 OS | miR-204, miR-211, miR-132/ SOX4, RUNX2, miR-204, SMAD4, miR-30, miR-124, IL-6, IL-10, TFN-α, CTNI/N1 | 4, 11, 12 |
| IncMALAT1  | upregulation           | oncogene              | huASCs, huFLSs, huFOB1,19, MG-63, U-2 OS, Saos-2 | miR-204, SMAD4, miR-30, miR-124, IL-6, IL-10, TFN-α, CTNIN1 | 4, 29, 111 |
| IncHOTAIR  | downregulation         | oncogene              | huBMScs, huAVICs, MG-63                    | miR-138, miR-204, miR17-5p/SMAD7 axis, Wnt/β-catenin signaling, NF-κB signaling | 107, 312–315 |
| IncH19     | upregulation           | oncogene              | raBMScs, raeMScs, MG-63, U-2 OS, Saos-2, HOB | Wnt/β-catenin signaling, miR-138, miR-149/ SDF-1 axis | 107, 312–315 |

ERK, extracellular signal-regulated kinase; MAPK, mitogen-activated protein kinase; AVIC, aortic valve interstitial cell.

The rapid development of molecular biology techniques, especially next-generation sequencing technologies such as RNA sequencing (RNA-seq), makes it possible to verify that non-coding transcripts are not only junk or "transcriptional noise," but also essential regulators of gene expression. Non-coding RNAs are engaged in many important biological processes, providing a unique regulatory mechanism for genes coding proteins, including morphogens and growth factors, which assure the proper development as well as homeostasis of an organism. There is a great need to explore this enormous world of functional classes of non-coding RNAs. In our opinion, special attention should be devoted to the identification and analysis of cross-talk between miRNAs, lncRNAs, and putative target genes. Evaluation of this functional network is crucial, notably in the view of better understanding of the molecular basis for the pathogenesis of lifestyle diseases, such as osteoporosis and RA. The analysis may also provide novel panels of biomarkers showing prognostic and diagnostic potential for bone-related diseases. Importantly, analysis of miRNA-lncRNA-mRNA crosstalk and networks may disclose new targets and allow the design of better therapies and therapeutic approaches, such as personalized medicine for bone disorders.

In this review, we have presented current knowledge related to the biology and function of miRNAs and lncRNAs that are involved in the process of osteogenesis and may find application as novel biomarkers for bone-related diseases. Several biotypes of non-coding RNAs, including miRNAs and lncRNAs, were identified in the cargo...
of extracellular vesicles released to the biological fluids. Thus, non-coding RNAs can act locally (in a paracrine and autocrine manner), as well as on adjacent cells. This is an important biological aspect that allows us to describe full panels of biomarkers, with paramount clinical importance in terms of personalized regenerative medicine for bone. It was shown that MALAT1 and TUG1 can serve as vital therapeutic targets, especially for osteoporosis patients. Due to affecting miR-30, miR-124, miR-204, and miR-211, presented lncRNAs are significantly engaged in the process of proper bone mineralization. Moreover, HOTAIR, by affecting miR-17-5p expression, may serve as a remarkable diagnostic and prognostic factor for tumor development and osteoporosis progression. Additionally, DANC4 can act as another essential therapeutic target, especially for the treatment of bone metabolic diseases. We strongly believe that the presented information on selected non-protein-coding RNA molecules will serve as an important impetus for preclinical investigations.

AUTHOR CONTRIBUTIONS
Concept of the Review, M.S. and A5; Graphical Work, M.S.; Writing – Original Draft, M.S. and A5; Writing – Review & Editing, M.S., A5, and K.M. All authors have read and agreed to the published version of the manuscript.

CONFLICTS OF INTEREST
The authors declare no competing interests.

ACKNOWLEDGMENTS
Substantive and financial support was obtained during the course of the completion of the Harmonia 10 project titled “New, two-stage scaffolds based on calcium nanoparticle (nHAP) incorporated with iron nanotubes (FeO2/Fe3O4) with the function of controlled release of miRNA in a static magnetic field for the regeneration of bone fractures in osteoporotic patients” (National Science Center (NCN) in Poland grant no. UMO 2017/26/M/NZ5/01184) is gratefully acknowledged. This work was co-financed by the Leading Research Groups support project from the subsidy increased for the period 2020–2025 in the amount of 2% of the subsidy referred to Art. 387 (3) of the Law of 20 July 2018 on Higher Education and Science, obtained in 2019.

REFERENCES
1. Ansari, M. (2019). Bone tissue regeneration: biology, strategies and interface studies. Prog. Biomater. 8, 223–257.
2. Turner, N.C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., et al.; PALOMA3 Study Group (2015). Palbociclib in hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 373, 209–219.
3. Hackl, M., Heilmeier, U., Weinler, S., and Grillari, J. (2016). Circulating microRNAs as novel biomarkers for bone diseases—complex signatures for multifactorial diseases? Mol. Cell. Endocrinol. 432, 83–95.
4. Peng, S., Cao, L., He, S., Zhong, Y., Ma, H., Zhang, Y., and Shuai, C. (2018). An overview of long noncoding RNAs involved in bone regeneration from mesenchymal stem cells. Stem Cells Int. 2018, 8273648.
5. Jathar, S., Kumar, V., Srivastava, J., and Tripathi, V. (2017). Technological developments in lncRNA biology. Adv. Exp. Med. Biol. 1008, 283–323.
6. Lu, T.X., and Rothenberg, M.E. (2018). MicroRNA. J. Allergy Clin. Immunol. 141, 1202–1207.
7. Cai, C.-K., Zhao, G.-Y., Tian, L.-Y., Liu, L., Yan, K., Ma, Y.-L., Ji, Z.W., Li, X.X., Han, K., Gao, J., et al. (2012). miR-15a and miR-16-1 downregulate CCND1 and induce apoptosis and cell cycle arrest in osteosarcoma. Oncol. Rep. 28, 1764–1770.
8. Mohr, A.M., and Mott, J.L. (2015). Overview of microRNA biology. Semin. Liver Dis. 35, 3–11.
9. O’Brien, J., Hayder, H., Zayed, Y., and Peng, C. (2018). Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front. Endocrinol. (Lausanne) 9, 402.
10. Dharap, A., Porepywa, C., Murali, S., Pandi, G., and Verunganti, R. (2013). MicroRNA miR-324-3p induces promoter-mediated expression of RbA gene. PLoS ONE 8, e79467.
11. Hua, Y., Jin, Z., Zhou, F., Zhang, Y.-Q., and Zhuang, Y. (2017). The expression significance of serum miR-21 in patients with osteosarcoma and its relationship with chemosensitivity. Eur. Rev. Med. Pharmacol. Sci. 21, 2989–2994.
12. Li, X., Guo, L., Liu, Y., Su, Y., Xie, Y., Du, J., Zhou, J., Ding, G., Wang, H., Bai, Y., and Liu, Y. (2017). MicroRNA-21 promotes osteogenesis of bone marrow mesenchymal stem cells via the Smad7-Smad1/5/8-Runx2 pathway. Biochem. Biophys. Res. Commun. 493, 928–933.
13. Gulyaeva, L.F., and Kushlinksky, N.E. (2016). Regulatory mechanisms of microRNA expression. J. Transl. Med. 14, 143.
14. Ha, M., and Kim, V.N. (2014). Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 15, 509–524.
15. Stavast, C.J., and Erkland, S.J. (2019). The non-canonical aspects of microRNAs: many roads to gene regulation. Cells 8, 1465.
16. Havens, M.A., Reich, A.A., Duelli, D.M., and Hastings, M.L. (2012). Biogenesis of mammalian microRNAs by a non-canonical processing pathway. Nucleic Acids Res. 40, 4626–4640.
17. Foessl, I., Kotzbeck, P., and Obermayer-Pietsch, B. (2019). miRNAs as novel biomarkers for bone related diseases. J. Lab. Precis. Med. 4, 2.
18. van Wijnen, A.J., van de Peppel, J., van Leeuwen, J.P., Lian, J.B., Stein, G.S., Westendorf, J.J., Oursler, M.J., Im, H.J., Taipaleenmäki, H., Hesse, E., et al. (2013). MicroRNA functions in osteogenesis and dysfunctions in osteoporosis. Curr. Osteoporos. Rep. 11, 72–82.
19. Bottani, M., Banfi, G., and Lombardi, G. (2019). Perspectives on miRNAs as epigenetic markers in osteoporosis and bone fracture risk: a step forward in personalized diagnosis. Front. Genet. 10, 1044.
20. Aich, M., and Chakraborty, D. (2020). Role of IncRNAs in stem cell maintenance and differentiation. Curr. Top. Dev. Biol. 138, 73–112.
21. Tye, C.E., Boyd, J.R., Page, N.A., Falcone, M.M., Stein, J.L., Stein, G.S., and Lian, J.B. (2018). Regulation of osteogenesis by long noncoding RNAs: an epigenetic mechanism contributing to bone formation. Connect. Tissue Res. 59 (Suppl. 1), 35–41.
22. Li, D., Yang, C., Yin, C., Zhao, F., Chen, Z., Tian, Y., Dang, K., Jiang, S., Zhang, W., Zang, G., and Qian, A. (2020). IncRNA, important player in bone development and disease. Endocr. Metab. Immune Disord. Drug Targets 20, 50–66.
23. Jiang, M.-C., Ni, J.-J., Cui, W.-Y., Wang, B.-Y., and Zhuo, W. (2019). Emerging roles of IncRNA in cancer and therapeutic opportunities. Am. J. Cancer Res. 9, 1354–1366.
24. Zhang, J., Hao, X., Yin, M., Xu, T., and Guo, F. (2019). Long non-coding RNA in osteogenesis: a new world to be explored. Bone Joint Res. 8, 73–80.
25. Smieszek, A., Marcinkowska, K., Piekol, A., Sikora, M., Valihrach, L., and Marycz, K. (2020). The role of miR-21 in osteoblasts-osteoclasts coupling in vitro. Cells 9, 479.
26. Qadir, A.S., Um, S., Lee, H., Bae, K., Seo, B.M., Lee, G., Kim, G.S., Woo, K.M., Ryoo, H.M., and Bae, J.H. (2015). miR-124 negatively regulates osteogenic differentiation and in vivo bone formation of mesenchymal stem cells. J. Cell. Biochem. 116, 730–742.
27. Valenti, M.T., Dalle Carbonare, L., and Mottes, M. (2018). Role of microRNAs in progenitor cell commitment and osteogenic differentiation in health and disease (Review). Int. J. Mol. Med. 41, 2441–2449.

28. Yang, N., Wang, G., Hu, C., Shi, Y., Liao, L., Shi, S., Cai, Y., Cheng, S., Wang, X., Liu, Y., et al. (2013). Tumor necrosis factor α suppresses the mesenchymal stem cell osteogenesis promoter miR-21 in estrogen deficiency-induced osteoporosis. J. Bone Miner. Res. 28, 559–573.

29. Liu, X.-G., Zhang, Y., Ju, W.-F., Li, C.-Y., and Mu, Y.-C. (2019). miR-21 relieves rheumatoid arthritis in rats via targeting Wnt signaling pathway. Eur. Rev. Med. Pharmacol. Sci. 23 (3, Suppl.), 96–103.

30. Xiong, G., Huang, Z., Jiang, H., Pan, Z., Xie, J., and Wang, S. (2016). Inhibition of microRNA-21 decreases the invasiveness of fibroblast-like synoviocytes in rheumatoid arthritis via TGF-β/Smads signaling pathway. Iran. J. Basic Med. Sci. 19, 787–793.

31. Zhou, W., Su, L., Duan, X., Chen, X., Hays, A., Upadhyayula, S., Shchve, J., Wang, H., Li, Y., Huang, D., and Liang, S. (2018). MicroRNA-21 down-regulates inflammaton and inhibits periodontitis. Mol. Immunol. 101, 608–614.

32. Nakka, M., Allen-Rhoades, W., Li, Y., Kelly, A.J., Shen, J., Taylor, A.M., Barkauskas, D.A., Yustein, J.T., Andrulis, I.L., Wunder, J.S., et al.; TARGET osteosarcoma consortium (2017). Biomarker significance of plasma and tumor miR-21, miR-221, and miR-106a in osteosarcoma. Oncotarget 8, 96738–96752.

33. Zhao, H., Yan, P., Wang, J., Zhang, Y., Zhang, M., Wang, Z., Fu, Q., and Liang, W. (2019). Clinical significance of tumor miR-21, miR-221, miR-143, and miR-106a as biomarkers in patients with osteosarcoma. Int. J. Mol. Markers 34, 184–195.

34. Lee, T.J., Yoo, J.Y., Shu, D., Li, H., Zhang, J., Yu, J.-G., Jaime-Ramirez, A.C., Acunzo, M., Romano, G., Cui, R., et al. (2017). RNA nanoparticle-based targeted therapy for glioblastoma through inhibition of enocrinogenic miR-21. Mol. Ther. 25, 1544–1555.

35. Ding, T., Cui, P., Zhou, Y., Chen, C., Zhao, J., Wang, H., Guo, M., He, Z., and Xu, L. (2018). Antisense oligonucleotides against miR-21 inhibit the growth and metastasis of colorectal carcinoma via the DUSP8 pathway. Mol. Ther. Nucleic Acids 13, 244–255.

36. Carthew, J., Donderwinkel, I., Shresta, S., Truong, V.X., Forrety, J.S., and Frith, J.E. (2020). In situ miRNA delivery from a hydrogel promotes osteogenesis of encapsulated mesenchymal stromal cells. Acta Biomater. 101, 249–261.

37. Meng, Y., Liu, C., Zhao, J., Li, X., Li, Z., Wang, J., Wang, R., Liu, Y., Yuan, X., Cui, Z., and Yang, X. (2016). An injectable miRNA-activated matrix for effective bone regeneration in vivo. J. Mater. Chem. B Mater. Biol. Med. 4, 6942–6954.

38. Moghadosi, M., Alivand, M., Fardi, M., Moghadam, K.S., and Solali, S. (2020). Microrna-216 – a potential diagnostic and prognostic marker for osteosarcoma. J. Bone Oncol. 9, 1299–1312.

39. Qiao, L., Liu, D., Li, C.-G., and Wang, Y.-J. (2018). miR-203 regulates osteoblast differentiation through GSKit by ankylosis spondylitis. Eur. Rev. Med. Pharmacol. Sci. 22, 6616–6624.

40. Tu, B., Liu, S., Yu, B., Zhu, J., Ruan, H., Tang, T., and Fan, C. (2016). miR-203 inhibits the traumatic heterotopic ossification by targeting Runx2. Cell Death Dis. 7, e2436.

41. Stanczyk, J., Ospelt, C., Kurozuzakis, E., Filer, A., Raza, K., Kolling, C., Gay, R., Buckley, C.D., Tak, P.P., Gay, S., and Kyburz, D. (2011). Altered expression of microRNA-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation. Arthritis Rheum. 63, 373–381.

42. Huang, W., Wu, Y., Cheng, D., and He, Z. (2020). Mechanism of epithelial-mesenchymal transition induced by miR-203 in non-small cell lung cancer. Oncol. Rep. 43, 457–466.

43. Márton, É., Lukács, J., Penyigé, A., Janka, E., Hegedüs, L., Behes, G., Póka, R., Nagy, B., and Szilágyi, M. (2019). Circulating epithelial-mesenchymal transition-associated miRNAs are promising biomarkers in ovarian cancer. J. Biotechnol. 297, 58–65.

44. Yang, D., Liu, G., and Wang, K. (2015). miR-203 acts as a tumor suppressor gene in osteosarcoma by regulating RARB22A. PLoS ONE 10, e0122225.

45. Lin, W., Zhu, X., Yang, S., Chen, X., Wang, L., Huang, Z., Ding, Y., Huang, L., and Lv, C. (2017). MicroRNA-203 inhibits proliferation and invasion, and promotes apoptosis of osteosarcoma cells by targeting Runx-related transcription factor 2. Biomed. Pharmacother. 91, 1075–1084.

46. Liu, S., and Feng, P. (2015). miR-203 determines poor outcome and suppresses tumor growth by targeting TBK1 in osteosarcoma. Cell. Physiol. Biochem. 37, 1956–1966.

47. Liu, T., Fu, N.-N., Song, H.-L., Wang, Y.-L., Wu, B.-J., and Shen, Z.-Y. (2014). microRNA-203 in osteosarcoma: a critical review through molecular mechanisms. Cell. Physiol. Biochem. 34, 1882–1892.

48. Chen, J., He, G., Wang, Y., and Cai, D. (2019). MicroRNA-223 promotes osteoblast differentiation of MC3T3-E1 cells by targeting histone deacetylase 3. J. Mol. Med. 43, 1513–1521.

49. Xie, Y., Zhang, L., Gao, Y., Gu, W., and Tang, P. (2015). The multiple roles of microRNA-223 in regulating bone metabolism. Molecules 20, 14933–14948.

50. Castro-Villegas, C., Pérez-Sánchez, C., Escudero, A., Filipec, I., Verdu, M., Ruiz-Limón, P., Aguirre, M.A., Jiménez-Gómez, Y., Font, P., Rodriguez-Arizá, A., et al. (2015). Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFα. Arthritis Res. Ther. 17, 49.

51. Dunaeva, M., Blom, J., Thurlings, R., and Pruijn, G.J.M. (2018). Circulating serum miR-223-3p and miR-16-5p as possible biomarkers of early rheumatoid arthritis. Clin. Exp. Immunol. 193, 376–385.

52. Ji, Q., Xu, X., Song, Q., Xu, Y., Tai, Y., Goodman, S.B., Bi, W., Xu, M., Jiao, S., Maloney, W.J., and Wang, Y. (2018). miR-223-3p inhibits human osteosarcoma metastasis and progression by directly targeting CDH6. Mol. Ther. 26, 1299–1312.

53. Dong, J., Liu, Y., Liao, W., Liu, R., Shi, P., and Wang, L. (2016). miRNA-223 is a potential diagnostic and prognostic marker for osteosarcoma. J. Bone Oncol. 5, 74–79.

54. Srinivasan, G., Williamson, E.A., Kong, K., Jaiswal, A.S., Huang, G., Kim, H.S., Schäfer, O., Zhao, W., Burma, S., Pong, P., and Hromas, R. (2019). miR223-3p
promotes synthetic lethality in BRCA1-deficient cancers. Proc. Natl. Acad. Sci. USA 116, 17438–17443.

66. Berenstein, R., Nogai, A., Weachechter, M., Blau, O., Kuchenbl, A., Schmidt-Hieber, M., Kunzit, A., Pezzuto, A., Dörken, B. and Blau, I.W. (2016). Multiple myeloma cells modify VEGF/FL-6 levels and osteogenic potential of bone marrow stromal cells via Nott/mir-223. Mol. Carcinog. 55, 1927–1939.

67. Chen, L., Song, Z., Huang, S., Wang, R., Qin, W., Guo, J., and Lin, Z. (2016). IncRNA DANC1 suppresses odontoblast-like differentiation of human dental pulp cells by inhibiting Wnt/b-catenin pathway. Cell Tissue Res. 364, 309–318.

68. Zhang, J., Tao, Z., and Wang, Y. (2017). Long non-coding RNA DANC1 regulates the proliferation and osteogenic differentiation of human bone-derived marrow mesenchymal stem cells via the p38 MAPK pathway. Int. J. Mol. Med. 41, 213–219.

69. Silva, A.M., Moura, S.R., Teixeira, J.H., Barbosa, M.A., Santos, S.G., and Almeida, F.C. (2019). Long noncoding RNAs: a missing link in osteoporosis. Bone Res. 7, 10.

70. Feldmann, M. (2002). Development of anti-TNF therapy for rheumatoid arthritis. Nat. Rev. Immunol. 2, 364–371.

71. Jiang, N., Wang, X., Xie, X., Liao, Y., Liu, N., Liu, J., Miao, N., Shen, J., and Peng, T. (2017). IncRNA DANC1 promotes tumor progression and cancer stemness features in osteosarcoma by upregulating AXL via miR-33a-5p inhibition. Cancer Letters, 456–55.

72. He, Q., Yang, S., Gu, X., Li, M., Wang, C., and Wei, F. (2018). Long noncoding RNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) promotes proliferation and metastasis of osteosarcoma cells by targeting c-Met and SOX4 via miR-34a-5p and miR-449a/b. Med. Sci. Monit. 25, 1410–1422.

73. Yang, G., Zhang, C., Wang, N., and Chen, J. (2019). miR-425-5p decreases IncRNA MALAT1 and TUG1 expressions and suppresses tumorigenesis in osteosarcoma via Wnt/b-catenin signaling pathway. Int. J. Biochem. Cell Biol. 111, 42–51.

74. Tornesello, M.L., Fararonio, R., Buonaguro, L., Annunziata, C., Starita, N., Cerasuolo, A., Pezzuto, F., Tornesello, A.L., and Buonaguro, F.M. (2020). The role of microRNAs, long non-coding RNAs, and circular RNAs in cervical cancer. Front. Oncol. 10, 130.

75. Chen, S., Zhang, C., and Feng, M. (2020). Prognostic value of IncRNA HOTAIR in colorectal cancer: a meta-analysis. Open Med. (Wars.) 15, 76–83.

76. Mozdarani, H., Ezzatizadeh, V., and Rahbar Parvaneh, R. (2020). The emerging role of the long non-coding RNA HOTAIR in breast cancer development and treatment. J. Transl. Med. 18, 152.

77. Zheng, H., and Min, J. (2016). Role of long noncoding RNA HOTAIR in the growth and apoptosis of osteosarcoma cell MG-63. BioMed Res. Int. 2016, 5757641.

78. Han, J., and Shen, X. (2020). Long noncoding RNAs in osteosarcoma via various signaling pathways. J. Clin. Lab. Anal. 34, 23317.

79. Wei, B., Wei, W., Zhao, B., Guo, X., and Liu, S. (2017). Long non-coding RNA HOTAIR inhibits miR-17-5p to regulate osteogenic differentiation and proliferation in non-traumatic osteonecrosis of femoral head. PLoS ONE 12, e0169097.

80. Shao, L., and Hou, C. (2019). miR-138 activates NF-kB signaling and PGRN to promote rheumatoid arthritis via regulating HDAC4. Biochem. Biophys. Res. Commun. 519, 166–171.

81. Zhang, J., Wei, Q.-F., Wang, S.-J., Zhang, H.-J., Zhang, X.-Y., Geng, Q., Cui, Y.H., and Wang, X.H. (2017). IncRNA HOTAIR alleviates rheumatoid arthritis by targeting miR-138 and inactivating NF-kB pathway. Int. Immunopharmacol. 50, 283–290.

82. Zhu, J., Yu, W., Wang, Y., Xia, K., Huang, Y., Xu, A., Chen, Q., Liu, B., Tao, H., Li, F., and Liang, C. (2019). IncRNAs: function and mechanism in cartilage development, degeneration, and regeneration. Stem Cell Res. Ther. 10, 344.

83. Han, J., and Chen, L. (2020). An integrated analysis of the competing endogenous RNA network and co-expression network revealed seven hub long non-coding RNAs in osteosarcoma. Bone Joint Res. 9, 90–98.

84. Cong, J., Zhang, S., and Gao, X. (2014). Quantitative assessment of the associations between CD28 T > C polymorphism (rs3116496) and cancer risk. Tumour Biol. 35, 9195–9200.

85. Shi, Z.-W., Wang, J.-L., Zhao, N., Guan, Y., and He, W. (2016). Single nucleotide polymorphism of hsa-miR-124a affects risk and prognosis of osteosarcoma. Cancer Biomark. 17, 249–257.

86. Dhanoa, J.K., Verma, R., Sethi, R.S., Arora, J.S., and Mukhopadhyay, C.S. (2019). Biogenesis and biological implications of isomiRs in mammals—a review. ExRNA 5, 3.

87. Li, H., Li, T., Wang, S., Wei, J., Fan, J., Li, J., Han, Q., Liao, L., Shao, C., and Zhao, R.C. (2013). miR-17-5p and miR-106a are involved in the balance between osteogenic and adipogenic differentiation of adipose-derived mesenchymal stem cells. Stem Cell Res. (Amst.) 10, 313–324.

88. Zhou, M., Ma, J., Chen, S., Chen, X., and Yu, X. (2014). MicroRNA-17-92 cluster regulates osteoblast proliferation and differentiation. Endocrine 49, 302–310.

89. Jia, J., Feng, X., Yu, W., Yang, S., Zhang, Q., Liu, X., Feng, Y., and Dai, Z. (2014). miR-17-5p regulates osteoblast differentiation and cell proliferation by targeting SMAD7 in non-traumatic osteoarthritis. Exp. Mol. Med. 46, e107.

90. Yang, H., Feng, Z., Liang, M., Zhang, Y., Yang, H., Huang, T., Jiang, Y., Jiang, B., and Wang, Y. (2018). The miR-17–92 cluster/QUAK12/B-catenin axis promotes osteosarcoma progression. Oncotarget 9, 25285–25293.

91. Wang, W., Zhang, L., Zheng, K., and Zhang, X. (2016). miR-17-5p promotes the growth of osteosarcoma in a BRCC2-dependent mechanism. Oncol. Rep. 35, 1473–1482.

92. Vanas, V., Haigl, B., Stockhammer, V., and Sutterlüty-Fall, H. (2016). MicroRNA-21 increases proliferation and cipal sensitiviy of osteosarcoma-derived cells. PLoS ONE 11, e0161023.
106. Wang, L., and Yu, J. (2019). The regulatory effect of Mir-149 on bone marrow mesenchymal stem cells in osteoporosis rats and its related mechanisms. J. Biomater. Tissue Eng. 9, 1127–1132.

107. Li, G., Yun, X., Ye, K., Zhao, H., An, J., Zhang, X., Han, X., Li, Y., and Wang, S. (2020). Long non-coding RNA-H19 stimulates osteogenic differentiation of bone marrow mesenchymal stem cells via the microRNA-149/SDF-1 axis. J. Cell. Mol. Med. 24, 4944–4955.

108. Xu, R.-D., Feng, F., Yu, X.-S., Liu, Z.-D., and Lao, L.-F. (2018). miR-149-5p inhibits cell growth by regulating TWEAK/Fn14/PI3K/AKT pathway and predicts favorable survival in human osteosarcoma. Int. J. Immunopathol. Pharmacol. 32, 2059738418786656.

109. Zhang, S., Liu, Y., Zheng, Z., Zeng, X., Liu, D., Wang, C., and Ting, K. (2018). MicroRNA-223 suppresses osteoblast differentiation by inhibiting DHR53. Cell. Physiol. Biochem. 47, 667–679.

110. Pan, Z., Wu, C., Li, Y., Li, H., An, Y., Wang, G., Dai, J., and Wang, Q. (2020). lncRNA DANCR silence inhibits SOX5-mediated progression and autophagy in osteosarcoma via regulating miR-216a-5p. Biomed. Pharmacother. 122, 109707.

111. Carrion, K., Dyo, J., Patel, V., Sasik, R., Mohamed, S.A., Hardiman, G., and Nigam, V. (2014). The long non-coding HOTAIR is modulated by cyclic stretch and WNT/β-CATENIN in human aortic valve cells and is a novel repressor of calcification genes. PLoS ONE 9, e96577.

112. Gong, Y.-Y., Peng, M.-Y., Yin, D.-Q., and Yang, Y.-F. (2018). Long non-coding RNA H19 promotes the osteogenic differentiation of rat ectomesenchymal stem cells via Wnt/β-catenin signaling pathway. Eur. Rev. Med. Pharmacol. Sci. 22, 8805–8813.

113. Wu, J., Zhao, J., Sun, L., Pan, Y., Wang, H., and Zhang, W.-B. (2018). Long non-coding RNA H19 mediates mechanical tension-induced osteogenesis of bone marrow mesenchymal stem cells via FAK by sponging miR-138. Bone 108, 62–70.

114. Zhao, J., and Ma, S.-T. (2018). Downregulation of IncRNA H19 inhibits migration and invasion of human osteosarcoma through the NF-κB pathway. Mol. Med. Rep. 17, 7388–7394.

115. Stuhlmüller, B., Kunisch, E., Franz, J., Martinez-Gambra, L., Hernandez, M.M., Pruss, A., Ulbrich, N., Erdmann, V.A., Burmester, G.R., and Kinne, R.W. (2003). Detection of oncofetal h19 RNA in rheumatoid arthritis synovial tissue. Am. J. Pathol. 163, 901–911.